Phase 4
Completed N=74
(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist
Source: ClinicalTrials.gov NCT03381261 ↗Enrolled (actual)
74
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcomePrimary: Inflammatory Gene Expression in Chronic Migraine Patients With OnabotulinumtoxinA Injection Treatment Versus No Treatment — 44.46156; 68.74241 mRNA units — p=<0.0001
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
To compare Botox-treated and Botox-untreated symptomatic tissues (defined as areas where the head hurts and the pain is felt) of chronic migraine (CM) patients using molecular studies.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Inflammatory Gene Expression in Chronic Migraine Patients With OnabotulinumtoxinA Injection Treatment Versus No Treatment |
44.46156; 68.74241 | <0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- Age 18-65 years
- Diagnosis of Chronic Migraine consistent with International Classification of Headache Disorders (ICHD-III) criteria, with a history of bilateral headache pain and chronic tenderness in neck muscles
- Patient is capable and willing to provide informed consent
- Female subjects of child bearing potential must have a negative pregnancy test at enrollment and agree to remain abstinent or use acceptable methods of birth control (i.e., hormonal contraceptives, inrauterine device, diaphragm with spermicide, cervical cap or sponge, condoms or partner has had a vasectomy) for three months following injections of Botox
- Patients referred by their primary Neurologist to the study surgeon and who are determined to be candidates for surgical decompression of extracranial sensory nerves.
- Patient agrees to abstain from protocol-specific excluded medications beginning 14 days prior to the decompression surgery.
Exclusion Criteria
- Patient has hypersensitivity reactions or other intolerance to Botox
- Patient is pregnant or trying to become pregnant with the timeframe of the study.
- Infection at proposed injection sites.
Data sourced from ClinicalTrials.gov (NCT03381261). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.